Match!
Powel H. Brown
Baylor College of Medicine
157Publications
30H-index
4,014Citations
Publications 158
Newest
Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer, and is associated with a poor prognosis due to frequent distant metastasis and lack of effective targeted therapies. Previously, we identified maternal embryonic leucine zipper kinase (MELK) to be highly expressed in TNBCs as compared with ER-positive breast cancers. Here we determined the molecular mechanism by which MELK is overexpressed in TNBCs. Analysis of publicly available data sets revealed that MELK mRNA ...
Source
#1Abhijit Mazumdar (University of Texas MD Anderson Cancer Center)H-Index: 22
#2William M. Tahaney (BCM: Baylor College of Medicine)H-Index: 1
Last.Powel H. Brown (BCM: Baylor College of Medicine)H-Index: 30
view all 8 authors...
Estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative, or “triple negative,” breast cancer (TNBC) is a poor prognosis clinical subtype that occurs more frequently in younger women and is commonly treated with toxic chemotherapy. Effective targeted therapy for TNBC is urgently needed. Our previous studies have identified several kinases critical for TNBC growth. Since phosphatases regulate the function of kinase signaling pathways, we sought to identify critical g...
1 CitationsSource
#1Katherine D. Crew (Columbia University)H-Index: 24
#2Garnet L. Anderson (Fred Hutchinson Cancer Research Center)H-Index: 68
Last.Powel H. Brown (University of Texas MD Anderson Cancer Center)H-Index: 30
view all 20 authors...
Observational studies have reported an inverse association between vitamin D intake and breast cancer risk. We examined whether vitamin D supplementation in high-risk premenopausal women reduces mammographic density (MD), an established breast cancer risk factor. We conducted a multicenter randomized double-blind placebo-controlled trial in premenopausal women at high risk for breast cancer [5-year risk ≥ 1.67%, lifetime risk ≥ 20%, lobular carcinoma in situ, prior stage 0–II breast cancer, here...
1 CitationsSource
#1Abhijit Mazumdar (University of Texas MD Anderson Cancer Center)H-Index: 22
#2Jamal Hill (University of Texas MD Anderson Cancer Center)H-Index: 13
Last.Powel H. Brown (University of Texas MD Anderson Cancer Center)H-Index: 30
view all 9 authors...
Background: Women with “triple-negative breast cancer” (TNBC), are currently treated with chemotherapy, and have a very poor prognosis. TNBC tumors also frequently have p53 and BRCA1 gene mutations. Dysregulation of PI3K-mTOR pathway has been commonly associated with ER-negative breast cancers with poor prognosis. The mTOR inhibitor everolimus is used to treat ER-positive tumors that have become resistant to anti-estrogen therapy. We hypothesized that targeting mTOR may prevent development of ER...
Source
#1Bora Lim (University of Texas MD Anderson Cancer Center)H-Index: 13
#2Rashmi Krishna Murthy (University of Texas MD Anderson Cancer Center)H-Index: 10
Last.Naoto T. Ueno (University of Texas MD Anderson Cancer Center)H-Index: 57
view all 22 authors...
Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model, an HDAC inhibitor epigenetically reversed the resistance of cancer cells to trastuzumab and showed synergistic efficacy with lapatinib in inhibiting growth of trastuzumab-resistant HER2-positive (HER2+) breast cancer. A phase 1b, dose escalation study was performed to assess maximum tolerated dose, ...
Source
#1Maria Fernanda Montiel (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Pompeyo Rafael Quesada (University of Texas MD Anderson Cancer Center)H-Index: 1
Last.Florencia McAllister (University of Texas MD Anderson Cancer Center)H-Index: 12
view all 18 authors...
1512Background: Genetic evolution studies have suggested the existence of a window of opportunity to improve clinical outcomes by intercepting pre-malignant lesions. This study reports the outcomes...
Source
Background: Breast cancer prevention with anti-estrogens, including tamoxifen, raloxifene, and exemestane, has been shown to reduce the incidence of hormone receptor-positive breast cancer. However, agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene are vitamin A analogues that have been shown to be involved in cell differentiation, growth, and apoptosis. In preclinical mouse models that develop ER-negative breast c...
Source
Last.Powel H. BrownH-Index: 30
view all 15 authors...
Source
#2Goli SamimiH-Index: 23
Last.Katherine D. CrewH-Index: 24
view all 17 authors...
Background: Denosumab is a monoclonal antibody that inhibits RANKL and is approved for the prevention of fractures in patients with osteoporosis or bone metastases. The RANKL signaling pathway is also involved in BRCA1-associated mammary tumorigenesis via a progesterone-induced paracrine effect of RANKL on luminal progenitor cells. Pre-clinical studies have demonstrated that RANKL inhibition resulted in reduced proliferation of mammary tumors. Early findings from an ongoing pre-surgical study de...
Source
#1Ernest Hawk (University of Texas MD Anderson Cancer Center)H-Index: 13
Last.Powel H. Brown (University of Texas MD Anderson Cancer Center)H-Index: 30
view all 3 authors...
Source
12345678910